Similar articles for PMID: 29986085

Year	Number of Results
1962	1
1979	1
1985	1
1986	1
2002	4
2003	4
2004	4
2005	4
2006	7
2007	5
2008	3
2009	10
2010	5
2011	9
2012	3
2013	5
2014	3
2015	7
2016	11
2017	8
2018	9
2019	6
2020	4
2021	9
2022	6
2023	2
2024	0

1

Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study.

Mayer G, Plazzi G, Iranzo Á, Ortega-Albás J, Quinnell T, Pesch H, Serralheiro P, Schlit AF, Wuiame D, Bentz JWG. Mayer G, et al. Sleep. 2018 Sep 1;41(9). doi: 10.1093/sleep/zsy128. Sleep. 2018. PMID: 29986085 Free article. Clinical Trial.

2

Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.

Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ. Bogan RK, et al. CNS Drugs. 2023 Apr;37(4):323-335. doi: 10.1007/s40263-023-00992-y. Epub 2023 Mar 22. CNS Drugs. 2023. PMID: 36947322 Free PMC article. Clinical Trial.

3

Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.

Plazzi G, Ruoff C, Lecendreux M, Dauvilliers Y, Rosen CL, Black J, Parvataneni R, Guinta D, Wang YG, Mignot E. Plazzi G, et al. Lancet Child Adolesc Health. 2018 Jul;2(7):483-494. doi: 10.1016/S2352-4642(18)30133-0. Epub 2018 May 21. Lancet Child Adolesc Health. 2018. PMID: 30169321 Clinical Trial.

4

Sodium oxybate for narcolepsy.

Scharf MB. Scharf MB. Expert Rev Neurother. 2006 Aug;6(8):1139-46. doi: 10.1586/14737175.6.8.1139. Expert Rev Neurother. 2006. PMID: 16893342 Review.

5

Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.

Husain AM, Bujanover S, Ryan R, Scheckner B, Black J, Profant J. Husain AM, et al. J Clin Sleep Med. 2020 Sep 15;16(9):1469-1474. doi: 10.5664/jcsm.8530. J Clin Sleep Med. 2020. PMID: 32356515 Free PMC article. Clinical Trial.

6

Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy.

U.S. Xyrem Multicenter Study Group. U.S. Xyrem Multicenter Study Group. Sleep Med. 2004 Mar;5(2):119-23. doi: 10.1016/j.sleep.2003.11.002. Sleep Med. 2004. PMID: 15033130 Clinical Trial.

7

Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.

Lecendreux M, Plazzi G, Dauvilliers Y, Rosen CL, Ruoff C, Black J, Parvataneni R, Guinta D, Wang YG, Mignot E. Lecendreux M, et al. J Clin Sleep Med. 2022 Sep 1;18(9):2217-2227. doi: 10.5664/jcsm.10090. J Clin Sleep Med. 2022. PMID: 35689598 Free PMC article. Clinical Trial.

8

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.

Dauvilliers Y, Šonka K, Bogan RK, Partinen M, Del Rio Villegas R, Foldvary-Schaefer N, Skowronski R, Chen A, Black J, Skobieranda F, Thorpy MJ. Dauvilliers Y, et al. CNS Drugs. 2022 Jun;36(6):633-647. doi: 10.1007/s40263-022-00926-0. Epub 2022 May 30. CNS Drugs. 2022. PMID: 35635687 Free PMC article. Clinical Trial.

9

Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.

[No authors listed] [No authors listed] Prescrire Int. 2007 Jun;16(89):98-101. Prescrire Int. 2007. PMID: 17582923

10

Sodium oxybate: a review of its use in the management of narcolepsy.

Robinson DM, Keating GM. Robinson DM, et al. CNS Drugs. 2007;21(4):337-54. doi: 10.2165/00023210-200721040-00007. CNS Drugs. 2007. PMID: 17381187 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

119 results

Results by year